Pharmacologic class (EPC) · 2 drug pages
Vitamin D analog: adverse event reports filed with FDA
12,441 reports list a drug in this class as a suspect or interacting product, 2004–2026.
- 12,441
- reports across the class
- 0.1% of all reports
- 88
- reports, 12 months to June 2026
- 66 in the 12 months before
- 87.8%
- marked serious by the reporter
- 57.4% across all reports
- 2
- drugs with a page
- brand and generic names counted separately
Vitamin D analog is a pharmacologic class (an FDA Established Pharmacologic Class) with 2 drug pages on this site. Together those drugs are listed as a suspect or interacting product in 12,441 adverse event reports received by FDA, 0.1% of the database, from July 2004 to June 2026.
88 reports arrived in the 12 months to June 2026, up 33% from 66 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. 87.8% of the class's reports are marked serious, 64% record death among the outcomes and 21.7% record hospitalisation, as reported.
Across the class the reactions recorded most often are death (27.7%), drug ineffective (5.1%) and cardiac disorder (4.8%). The class median share shown beside each term is the middle value across the member drugs; it is the comparison used on every drug page in this class.
The members table is ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Drugs in the class
| Drug | Name type | Reports | Latest 12 months | Marked serious | Top term recorded |
|---|---|---|---|---|---|
| ZemplarParicalcitol | brand | 11,348 | 5 | 93.6% | Death |
| Calcipotriene | generic | 1,093 | 83 | 27.4% | Drug ineffective |
Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Reports by month, five years
FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.
Reactions recorded across the class
share of class reports recording the termmedian drug in the class
- Deaththe patient died; cause not stated by this term27.7%3,440
- Drug ineffectivethe medicine did not work as expected5.1%637
- Cardiac disorder4.8%603
- Myocardial infarctionheart attack4.3%537
- Cardio-respiratory arrestthe heart and breathing stopped3.5%436
- Sepsisa severe body-wide response to infection3.2%396
- Cardiac failureheart failure2.4%301
- Psoriasispsoriasis, a skin condition2.3%288
- Infarction2%253
- Cerebrovascular accidentstroke2%247
- Dyspnoeashortness of breath1.8%223
- Cardiac arrestthe heart stopped1.7%213
- Adverse eventan unwanted medical event, type not specified1.6%194
- Pneumonialung infection1.5%189
- Infectionan infection, type not specified1.5%188
- Respiratory arrestbreathing stopped1.5%188
- Falla fall1.4%176
- General physical health deteriorationgeneral decline in health1.4%168
- Acute myocardial infarction1.3%164
- Renal transplant1.3%157
- Pyrexiafever1.3%156
- Arthralgiajoint pain1.2%152
- Cardiovascular disorder1.2%151
- Pruritusitching1.2%151
- Fatiguetiredness1.2%149
Solid bar: share of all class reports. Hollow bar: the median share across the 2 member drugs, the reference used on each member's page. One report can record several terms.
Outcomes, patients and reporters
Outcomes recorded
Patient age
Who reported
Grey bar: all 20,646,523 reports in the database. Outcome flags are as the reporter set them and are not verified by FDA.
Questions about Vitamin D analog reports
Which drugs are in the Vitamin D analog class on this site?
Zemplar and Calcipotriene. Class membership comes from the pharmacologic class (EPC) on the drug's FDA label.
How many reports does the class have?
12,441 reports through June 2026, 88 of them in the latest 12 months. A report listing two drugs of the class counts once for each.
What reactions are recorded most often?
death (27.7%), drug ineffective (5.1%), cardiac disorder (4.8%), myocardial infarction (4.3%) and cardio-respiratory arrest (3.5%).
Can the members table be used to rank the drugs?
No. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." Drugs differ in how many people take them, in the conditions they treat, in time on the market and in how diligently reports are collected.
How do I report an adverse event?
Through FDA MedWatch (Form FDA 3500, or 1-800-FDA-1088) or to the manufacturer. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A class is the Established Pharmacologic Class most often attached to a drug's reports by openFDA's label harmonisation, or from the NDC Directory where reports carry none. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.